{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Graphical and numerical studies of bivariate relationships will be examined, as well as factors (i.e., tumor size, tumor location, patient age) to explain concurrence, lack of concurrence, and sources of measurement error for measurements of ER function.","groups":[{"description":"Patients undergo \\[\\^18F\\] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to \\[\\^18F\\] FES PET scan.\n\nPatients begin clinically indicated endocrine therapy.\n\nPatients are followed-up to determine response on the therapy for 6 months using clinical exams, tumor marker assays, conventional imaging and standard clinical FDG PET/CT.\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Diagnostic (FES)"}],"populationDescription":"Data were not collected due to variations in reporting methods for ER assays.","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Correlation of FES Uptake With ER Assays","type":"SECONDARY"}